MarginsXMarginsX
Home › Markets › Health Care › NUVB

Nuvation Bio Inc. (NUVB)

NUVB trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.84
-3.76% on the day
Market cap
$1.4B
Small cap
Revenue · 2025
$62.9M
+699.0% on 2024
Net income · 2025
-$204.6M
-325.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1811063/000119312526085584/0001193125-26-085584-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerNUVB on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001811063
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$62.9M
Net income-$204.6M
Operating income-$213.1M
Net margin-325.3%
Operating margin-338.7%
Revenue growth+699.0%
Cash$164.1M
Total assets$594.8M
P/E (computed)Net income was not positive
P/S (computed)21.6×

Warning signs

Cash runway
17.4 months
$153.8M cash at September 30, 2026
Share count, 1 year
+3.0%
2025-10-24 to 2026-10-30 · +61.2% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$9.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$153.8M cash; operating cash flow -$26.5M a quarter.Report 2026-09-30
Shares outstanding353,017,638 (2026-10-30); 342,833,433 a year earlier; 218,944,053 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-06-29
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2026-02-10
AuditorKPMG LLP, New York, New York, United StatesPCAOB Form AP 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $118K, sold $9.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$45.0M-$41.9M-$38.6M$153.8M$285.4M$201.7M10-Q 2026-11-04
Q2 2026
2026-06-30
$31.7M-$62.8M-$43.0M$258.6M$248.5M$169.9M10-Q 2026-08-06
Q1 2026
2026-03-31
$83.2M$5.4M$5.1M$125.4M$53.1M$143.0M10-Q 2026-05-04
Q4 2025
2025-12-31
$41.9M-$36.6M-$29.7M$164.1M$52.9M$62.9M10-K 2026-03-02
Q3 2025
2025-09-30
$13.1M-$55.8M-$52.9M$98.9M$52.7M$26.7M10-Q 2026-11-04
Q2 2025
2025-06-30
$4.8M-$59.0M-$48.2M$248.0M$52.6M$14.4M10-Q 2026-08-06
Q1 2025
2025-03-31
$3.1M-$53.2M-$42.6M$48.0M$5.7M$11.0M10-Q 2026-05-04
Q4 2024
2024-12-31
$5.7M-$49.4M-$46.3M$35.7M$6.3M$7.9M10-K 2026-03-02

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-06-29
Latest annual report10-K2026-03-02
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 400 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.1%
1 month-15.5%
3 months-34.6%
Year to date-55.5%
1 year-14.9%
From 52-week high-58.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GENBGenerate Biomedicines Inc.$10.49-13.09%$1.4B
ANABAnaptysBio Inc.$45.73-1.12%$1.4B
TYRATyra Biosciences Inc.$19.74-1.42%$1.4B
URGNUroGen Pharma Ltd.$28.10+7.33%$1.4B
GPCRStructure Therapeutics Inc.$18.57-7.15%$1.3B
AVLNAvalyn Pharma Inc.$29.76-1.72%$1.3B
OCULOcular Therapeutix Inc.$6.01-3.22%$1.3B
LBRXLB Pharmaceuticals Inc$42.99-0.05%$1.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier